Slxn stock forecast the SLXN stock forecast benefits from

The SLXN stock forecast benefits from improving sentiment in the semiconductor-adjacent tech sub-sector, where supply chain normalization could contribute to margin stabilization and share price expansion. What is the current Price Target and Forecast for Silexion ... Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com SLXN stock forecast trends in June 2024 suggest the stock may outperform peers if quarterly EPS beats consensus by 5% or more, a scenario supported by management's optimism in current guidance calls.